Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib in Relapsed/Refractory Leukemia and MPNs
NCT01167166Phase 2Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Jul 2010
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rigosertib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), sponsored by Traws Pharma, Inc.. Started Jul 2010; status: completed.
02
Drugs
rigosertib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myeloproliferative neoplasms (MPN)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01167166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01167166.